kaonavi
4435
D. Western Therapeutics Institute
4576
Itamiarts
168A
Nakayo
6715
Allied Telesis Holdings KK
6835
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 18.11%49.9B | 10.92%44.87B | -9.67%165.51B | -1.73%40.35B | -10.98%42.25B | -11.79%42.46B | -13.14%40.46B | 11.95%183.22B | -1.46%41.06B | 10.85%47.46B |
Cost of revenue | 13.85%26.79B | 13.24%24.67B | -2.13%93.01B | 2.36%23.39B | -3.13%23.53B | 0.58%24.31B | -8.19%21.79B | 7.11%95.04B | 0.69%22.85B | 7.02%24.29B |
Gross profit | 23.46%23.12B | 8.21%20.2B | -17.79%72.5B | -6.87%16.96B | -19.20%18.73B | -24.27%18.15B | -18.28%18.67B | 17.67%88.19B | -4.03%18.21B | 15.16%23.17B |
Operating expense | 28.03%11.12B | 3.41%9.94B | -7.14%38.48B | -8.57%10.17B | -18.65%8.69B | 2.56%10.02B | -2.65%9.61B | 21.24%41.44B | 20.58%11.13B | 19.98%10.68B |
Selling and administrative expenses | 30.97%11.08B | 5.83%10.01B | -9.00%37.24B | -7.73%9.61B | -21.09%8.46B | -1.25%9.71B | -4.96%9.46B | 19.81%40.92B | 13.13%10.42B | 21.38%10.72B |
-General and administrative expense | 30.97%11.08B | 5.83%10.01B | -9.00%37.24B | -7.73%9.61B | -21.09%8.46B | -1.25%9.71B | -4.96%9.46B | 19.81%40.92B | 13.13%10.42B | 21.38%10.72B |
Other operating expenses | -60.38%124M | -87.60%31M | 46.90%1.61B | -33.54%644M | 469.09%313M | 698.04%407M | 1,036.36%250M | 143.46%1.1B | 368.12%969M | -63.58%55M |
Total other operating income | -2.22%88M | 4.08%102M | -36.32%370M | -68.60%81M | -11.76%90M | -14.41%101M | -3.92%98M | 36.38%581M | 38.71%258M | 17.24%102M |
Operating profit | 19.51%12B | 13.29%10.26B | -27.24%34.02B | -4.21%6.79B | -19.67%10.04B | -42.72%8.13B | -30.18%9.06B | 14.68%46.75B | -27.32%7.08B | 11.33%12.5B |
Net non-operating interest income (expenses) | 77.57%1.62B | -0.88%1.58B | 157.83%4.74B | 156.41%1.34B | 220.11%914M | 65.13%895M | 3.84%1.6B | -20.55%1.84B | -55.15%523M | -236.38%-761M |
Non-operating interest income | -14.22%1.17B | -1.66%1.6B | 120.98%4.84B | 98.40%1.36B | 92.11%1.36B | 62.63%927M | 4.08%1.63B | -8.57%2.19B | -43.73%687M | 25.66%710M |
Non-operating interest expense | -200.67%-453M | -36.11%23M | -73.85%91M | -86.59%22M | -69.41%450M | 14.29%32M | 16.13%36M | 351.95%348M | 198.18%164M | 20,914.29%1.47B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 24.36%13.62B | 11.17%11.84B | -20.23%38.76B | 6.84%8.13B | -6.67%10.95B | -38.75%9.03B | -26.57%10.65B | 12.79%48.59B | -30.29%7.61B | -0.40%11.74B |
Income tax | 25.79%3.57B | -25.76%3.44B | -11.92%12.28B | 7.86%2.36B | -9.73%2.84B | -41.00%2.45B | 3.95%4.63B | 19.74%13.94B | -32.91%2.19B | 12.53%3.14B |
Net income | 23.85%10.05B | 39.58%8.4B | -23.57%26.48B | 6.42%5.77B | -5.55%8.12B | -37.87%6.58B | -40.10%6.02B | 10.21%34.65B | -29.18%5.42B | -4.42%8.59B |
Net income continuous operations | 23.85%10.05B | 39.58%8.4B | -23.57%26.48B | 6.42%5.77B | -5.55%8.12B | -37.87%6.58B | -40.10%6.02B | 10.21%34.65B | -29.18%5.42B | -4.42%8.59B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 23.85%10.05B | 39.58%8.4B | -23.57%26.48B | 6.42%5.77B | -5.55%8.12B | -37.87%6.58B | -40.10%6.02B | 10.21%34.65B | -29.18%5.42B | -4.42%8.59B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 23.85%10.05B | 39.58%8.4B | -23.57%26.48B | 6.42%5.77B | -5.55%8.12B | -37.87%6.58B | -40.10%6.02B | 10.21%34.65B | -29.18%5.42B | -4.42%8.59B |
Gross dividend payment | ||||||||||
Basic earnings per share | 25.75%297.08 | 42.04%248.41 | -22.92%772.38 | 7.88%170.34 | -5.36%236.25 | -37.89%190.97 | -39.04%174.89 | 13.17%1K | -27.03%157.9 | -1.84%249.62 |
Diluted earnings per share | 25.76%297.08 | 42.05%248.4 | -22.91%772.33 | 7.89%170.34 | -5.35%236.23 | -37.89%190.96 | -39.04%174.87 | 13.19%1K | -27.02%157.88 | -1.83%249.58 |
Dividend per share | 0 | 0 | -12.00%440 | -21.43%220 | 0 | 0.00%220 | 0 | 13.64%500 | 0.00%280 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |